Navigation Links
Nektar to Announce Financial Results for the First Quarter of 2009 on Wednesday, May 6, 2009, After Close of U.S.-Based Financial Markets
Date:4/29/2009

SAN CARLOS, Calif., April 29 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2009 on Wednesday, May 6, 2009, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Wednesday, May 20, 2009.

        To access the conference call, follow these instructions:

        Dial: (888) 396-2369 (U.S.); (617) 847-8710 (international)
        Passcode: 82263149 (Howard Robin is the host)

An audio replay will also be available shortly following the call through Wednesday, May 20, 2009 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 19053055.

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products f
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
2. Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets
3. Nektar Therapeutics Announces Second Quarter 2008 Results
4. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
5. Nektar Therapeutics Announces First Quarter 2008 Results
6. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
7. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
8. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
10. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
11. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... Young men who believe that happiness declines wit...haviors such as binge drinking. Their misguided ne...ncentive to behave ,sensibly, and encourage them t...,miserable, old age. These findings 1 by Dr. Joh...y Belfast, Northern Ireland, are published online ...
(Date:12/1/2009)... Lumension announces gener... Security Suite to deliver end-to-end endpoint man...ent and single management console architecture. ,...cember 1, 2009 -- Lumension, a global leader in en... new Lumension® Endpoint Management and Secur...
(Date:12/1/2009)..., , SAN DIEGO, Dec. 1 /PRNewswire-First... supplier of Farming, Nursery and Wellness product... agreement with Southern California Micro-Lending .... ,, Yan Skwara, CEO of US Farms, Inc. stated,...rtnership with Angels in Action utilizing our Aloe...
(Date:12/1/2009)...ong-lasting effects on brain seen by researchers u...1 (HealthDay News) -- Childhood exposure to lead c...ound. , "What we have found is that no region o... areas of the brain are affected differently," stu...nnati Children,s Hospital Medical Center and a pro...
(Date:12/1/2009)... Chevy Chase, MD According to a new study accepted...al of Clinical Endocrinology & Metabolism ( JCEM ...to have abnormal insulin resistance. Having abnor...t heart, blood vessel and exercise function in thi... childhood. Patients with type 2 diabetes have the...
Breaking Medicine News(10 mins):Health News:Binge drinking youths find getting old a drag 2Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 2Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 3Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 4Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 5Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 6Health News:US Farms, Inc. Announces Marketing Agreement With Micro Lending Institution Angels In Action 2Health News:US Farms, Inc. Announces Marketing Agreement With Micro Lending Institution Angels In Action 3Health News:Childhood Lead Exposure Causes Permanent Damage: Study 2Health News:Cardiovascular risk in youth with type 1 diabetes linked primarily to insulin resistance 2
...rn Foundation launches fourth phase of firefighter...l 20 Continuing in the tradition of providing inn...rvice the People,s Burn Foundation is pleased to u... body through advanced 3-D visualizations to revea...
...molive,s ,Share Mom,s Love, Contest to Award Fundi...l 20. 2009 Colgate-Palmolive has partnered with S...tarting with just a click of a mouse. To coincide ...rams to select cities in the U.S. , , Over 12.6 ...
..., April 20 INDUS Corporation, a leading Federal I...ounced today that it has been awarded an IT data a...my Medical Command (MEDCOM), Office of the Surgeon...rseas and state-side Military Treatment Facilities...
..., April 20 In direct response to America,s aging ...care, healthcare professionals recently gathered i...ss one of the nation,s most pressing healthcare ne...ly more efficient and less costly," said Dan Oster...
...a -- Parents have been saying for years that their...dy by an Iowa State University psychology professo...l patterns of video game addiction exist in a nati...uglas Gentile found nearly one in 10 of the gamers...
...ter valve implantation is a newly developed techni...c stenosis. It is likely to be of benefit especial...isk of open heart surgery would be too great. The ...onal by Sabine Bleiziffer and her colleagues (Dts...
Other Medicine News:Health News:Discover the Deadly Toxic Twins: Hydrogen Cyanide and Carbon Monoxide 2Health News:Discover the Deadly Toxic Twins: Hydrogen Cyanide and Carbon Monoxide 3Health News:Discover the Deadly Toxic Twins: Hydrogen Cyanide and Carbon Monoxide 4Health News:Colgate-Palmolive Partners With Share Our Strength To Host Online Contest To Combat Childhood Hunger 2Health News:Colgate-Palmolive Partners With Share Our Strength To Host Online Contest To Combat Childhood Hunger 3Health News:Healthcare Gathering Addresses Increasing Need of Caring for the Nation's Elderly Population 2Health News:Healthcare Gathering Addresses Increasing Need of Caring for the Nation's Elderly Population 3Health News:National study finds nearly 1 in 10 youth gamers addicted to video games 2Health News:Valve implantation on the beating heart 2
(Date:12/1/2009)...ATAWAY, N.J., Dec. 1 Siemens Hear...ng) a leading global manufacturer of hearing instr...h Quota International,s Sound Beginnings program. ...010. ,, As part of the renewed partnership, Sie...for 100 free hearing instruments to both children ...
(Date:12/1/2009)...GO, Dec. 1 ADVENTRX Phar...ed that a new, recently completed preclinical stud...oxicity of ANX-514 and Taxotere® (docetaxel)....or ANX-514 in South Korea, independently conducted...dent confirmation of the bioequivalence and compar...
(Date:12/1/2009)...LE, Md., Dec. 1 Vanda Ph...y that the waiting period has expired under the Ha...f 1976 with respect to Vanda,s agreement, dated Oc...the agreement is now effective. Expiration of the...f the agreement, triggers an upfront payment to Va...
Breaking Medicine Technology:Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 2Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 3ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514 2ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514 3Boston Scientifics Urology Gynecology Products Featured in Studies at International Urogynecological Association Annual Meeting 48889 1Boston Scientifics Urology Gynecology Products Featured in Studies at International Urogynecological Association Annual Meeting 48889 2Boston Scientifics Urology Gynecology Products Featured in Studies at International Urogynecological Association Annual Meeting 48889 3Boston Scientifics Urology Gynecology Products Featured in Studies at International Urogynecological Association Annual Meeting 48889 4Boston Scientifics Urology Gynecology Products Featured in Studies at International Urogynecological Association Annual Meeting 48889 5Boston Scientifics Urology Gynecology Products Featured in Studies at International Urogynecological Association Annual Meeting 48889 6HITSP Begins Harmonization Process for Use of Electronic Health Records in Clinical Research 48886 1HITSP Begins Harmonization Process for Use of Electronic Health Records in Clinical Research 48886 2HITSP Begins Harmonization Process for Use of Electronic Health Records in Clinical Research 48886 3HITSP Begins Harmonization Process for Use of Electronic Health Records in Clinical Research 48886 4Cynvec to Present at The 2009 New York Venture Summit 12624 1Cynvec to Present at The 2009 New York Venture Summit 12624 2
...Patient Cohort Enrolled in Stage A of Trial Assess...Carboplatin and Paclitaxel -, TUSTIN, Calif., Oct...M ), a clinical stage biopharmaceutical,company de...f cancer and,hepatitis C virus (HCV) infection, to...the first stage of a Phase II trial of bavituximab...
...PPENHAM, England, October 7 ,Sosei Group Corporati...Group plc ("Vectura"; LSE: VEC), announce results ...afety and tolerability of NVA237 presented at the,...y (ERS) in Berlin,Germany. The new data show that ...ong-acting muscarinic antagonist (LAMA), provides ...
Other Medicine Technology:Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
Medicine Products: